Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

Jurjen Versluis, MD, Carin L.E. Hazenberg, MD, Wim van Putten, MSc, Jakob R Passweg, MD, Johan Maertens, MD PhD, Bart J Biemond, MD PhD, Harry C Schouten, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MDPhD, Edo Vellenga, MDPhD, Jan J Cornelissen, MD PhD

Blood (2014) 124 (21): 321.

https://doi.org/10.1182/blood.V124.21.321.321

Published: 2014

Journal Articles

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Blood (2014) 124 (21): 323.

https://doi.org/10.1182/blood.V124.21.323.323

Published: 2014

Journal Articles

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Marie-Christiane Vekemans, Bart Biemond, Peter Sonneveld, Jakob Passweg, Leo Verdonck, Marie-Cecile Legdeur, Matthias Theobald, Emanuel Jacky, Mario Bargetzi, Johan Maertens, Gert Jan Ossenkoppele, Bob Löwenberg

Blood (2012) 119 (23): 5367–5373.

https://doi.org/10.1182/blood-2011-11-389841

Published: 2012

Includes: Supplemental data

Journal Articles

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Leo F. Verdonck, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Alois Gratwohl, Ron Schaafsma, Urs Schanz, Carlos Graux, Harry C. Schouten, Augustin Ferrant, Mario Bargetzi, Martin F. Fey, Bob Löwenberg, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Blood (2011) 118 (23): 6037–6042.

https://doi.org/10.1182/blood-2011-07-370247

Published: 2011

Includes: Supplemental data

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

Journal Articles

Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission

Edo Vellenga, MD, PhD, Wim van Putten, MD, PhD, Gert J. Ossenkoppele, MD, PhD, Martin Fey, MD, Jurgen Kuball, MD, PhD, Matthias Theobald, MD, PhD, Jan J. Cornelissen, MD, PhD, Peter Huijgens, MD, PhD, Johan Maertens, Alois Gratwohl, MD, Martyn Ronald Schaafsma, MD, PhD, Markus G Manz, MD, Carlos Graux, MD, PhD, Bob Lowenberg, MD, PhD

Blood (2010) 116 (21): 367.

https://doi.org/10.1182/blood.V116.21.367.367

Published: 2010

Journal Articles

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Blood (2010) 115 (13): 2586–2591.

https://doi.org/10.1182/blood-2009-10-246470

Published: 2010

Journal Articles

Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia

Jan J. Cornelissen, Wim van Putten, Bob Löwenberg

Blood (2007) 110 (13): 4619–4620.

https://doi.org/10.1182/blood-2007-08-105650

Published: 2007

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

Roel G. W. Verhaak, Chantal S. Goudswaard, Wim van Putten, Maarten A. Bijl, Mathijs A. Sanders, Wendy Hugens, André G. Uitterlinden, Claudia A. J. Erpelinck, Ruud Delwel, Bob Löwenberg, Peter J. M. Valk

Blood (2005) 106 (12): 3747–3754.

https://doi.org/10.1182/blood-2005-05-2168

Published: 2005

Includes: Supplemental data

Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD

Blood (2005) 106 (11): 16.

https://doi.org/10.1182/blood.V106.11.16.16

Published: 2005

NARROW

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only